11 Most Undervalued Growth Stocks to Buy According to Hedge Funds

Page 6 of 10

​5. Amgen Inc. (NASDAQ:AMGN)

Forward P/E Ratio: 13.57

Number of Hedge Fund Holders: 62

​Amgen Inc. (NASDAQ:AMGN) is one of the Most Undervalued Growth Stocks to Buy According to Hedge Funds. On September 22, Amgen Inc.’s (NASDAQ:AMGN) and AstraZeneca’s Tezspire received a positive recommendation from the European Medicines Agency Committee for Medicinal Products for Human Use.

​The approval is for treating adults with chronic rhinosinusitis with nasal polyps in the European Union. The recommendation is based on the results from the Phase III WAYPOINT trial, which showed that Tezspire significantly reduced nasal polyp size and nasal congestion compared to placebo after one year. Moreover, patients experienced a nasal polyp score reduction of -2.08 and a nasal congestion score drop of -1.04, both statistically significant.

​Notably, Tezspire helped nearly eliminate the need for surgery and greatly reduced systemic corticosteroid use by 89%. These findings address key challenges for CRSwNP patients who often suffer from repeated surgeries and long-term steroid side effects.

​Amgen Inc. (NASDAQ:AMGN) is a biotechnology company that discovers, develops, and manufactures medicines for serious diseases.

Page 6 of 10